Gilead, Leo Pharma
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...
Hosted on MSN1d
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Zacks.com on MSN2d
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The stock's rise snapped a five-day losing streak.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback